Skip to content
SLNSilence Therapeutics plc

Earnings

When Silence Therapeutics plc reports, what it reported each quarter, and how the stock took the results.

11 quarters. Mar 31, 2024 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 4, before the open

Thu, Mar 4, 2027in 106 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 22 – Mar 12

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$34.00K
Revenue, change from a year earlier: Q3 2026 −100.0%, Q2 2026 −100.0%, Q1 2026 +197.2%, Q4 2025 −99.9%
Net income
-$11.77M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$0.00−100.0% vs Q3 2025

Latest results

  1. Q3 2026Nov 12, 2026, before the openThe release
    Revenue
    $0.00
    −100.0%
    Net income
    -$12.43M
    N/M
    EPS
    -$0.08
    N/M
    On October 19, 2026, Silence announced ( press release ) that it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany.
  2. Q2 2026Aug 10, 2026, before the openThe release+29.3%by the close of Aug 10
    Revenue
    $0.00
    −100.0%
    Net income
    -$12.27M
    N/M
    EPS
    -$0.09
    N/M
  3. Q1 2026May 7, 2026, before the openThe release5.6%by the close of May 7
    Revenue
    $422.00K
    +197.2%
    Net income
    -$14.96M
    N/M
    EPS
    -$0.11
    N/M
  4. Q4 2025Mar 5, 2026, before the openThe release4.6%by the close of Mar 5
    Revenue
    $34.00K
    −99.9%
    Net income
    -$11.77M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 12, 2026 · pre-marketNov 13, 202644 d10-Q$0.00−100.0%-$0.08—
Q2 2026Jun 30, 2026Aug 10, 2026 · pre-marketAug 10, 202641 d10-Q$0.00−100.0%-$0.09+29.3%
Q1 2026Mar 31, 2026May 7, 2026 · pre-marketMay 7, 202637 d10-Q$422.00K+197.2%-$0.115.6%
FY 2025
Q4 2025derivedDec 31, 2025Mar 5, 2026 · pre-marketMar 5, 202664 d10-K$34.00K−99.9%—4.6%
Q3 2025Sep 30, 2025Nov 6, 2025 · pre-marketNov 6, 202537 d10-Q$159.00K−89.4%-$0.15+3.4%
Q2 2025Jun 30, 2025Aug 7, 2025 · pre-marketAug 7, 202538 d10-Q$224.00K−70.4%-$0.190.2%
Q1 2025Mar 31, 2025May 8, 2025 · pre-marketMay 8, 202538 d10-Q$142.00K−99.1%-$0.203.8%
FY 2024
Q4 2024derivedDec 31, 2024Feb 27, 2025 · after-hoursFeb 27, 202558 d10-K$25.31M——5.2%
Q3 2024Sep 30, 2024————$1.50M—-$0.25—
Q2 2024Jun 30, 2024————$756.00K—-$0.14—
Q1 2024Mar 31, 2024————$15.70M—-$0.02—

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 13, 2026458896
10-QAug 10, 2026341248
10-QMay 7, 2026210446
10-KMar 5, 2026092591
10-QNov 6, 2025268116
10-QAug 7, 2025104593
10-QMay 8, 2025066439
10-KFeb 27, 2025029129

Provenance

ProvenanceData status and checks

Silence Therapeutics plc · CIK 1479615 · Engraved from SEC EDGAR